Literature DB >> 15183342

'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus.

Jason W Rausch1, Stuart F J Le Grice.   

Abstract

During the course of reverse transcription, human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) initiates plus-strand DNA synthesis from two highly conserved, purine-rich RNA segments of the viral genome referred to as the 3' and central polypurine tracts (3' and cPPTs). Processing of these elements occurs in several sequential steps including (1) minus-strand DNA synthesis over the PPT(s), (2) ribonuclease H (RNase H) mediated cleavage at the PPT 3' terminus, (3) plus-strand DNA synthesis from the nascent RNA primer(s), and (4) primer removal. Completing each of these steps precisely and specifically is essential, as failure to do so can result in reduced virus replication and/or impaired integration of viral DNA into the host cell genome. In this review, plus-strand primer processing in HIV-1 is discussed from biochemical, structural, and historical perspectives. A comparative analysis of PPT-processing in different LTR-containing retroelements is also presented. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183342     DOI: 10.1016/j.biocel.2004.02.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  55 in total

Review 1.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  Structure of HIV-1 reverse transcriptase bound to a novel 38-mer hairpin template-primer DNA aptamer.

Authors:  Matthew T Miller; Steve Tuske; Kalyan Das; Jeffrey J DeStefano; Eddy Arnold
Journal:  Protein Sci       Date:  2015-09-18       Impact factor: 6.725

3.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

4.  Specific recognition and cleavage of the plus-strand primer by reverse transcriptase.

Authors:  Angela Atwood-Moore; Kenechi Ejebe; Henry L Levin
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Sequence, distance, and accessibility are determinants of 5'-end-directed cleavages by retroviral RNases H.

Authors:  Sharon J Schultz; Miaohua Zhang; James J Champoux
Journal:  J Biol Chem       Date:  2005-11-22       Impact factor: 5.157

6.  Tighter binding of HIV reverse transcriptase to RNA-DNA versus DNA-DNA results mostly from interactions in the polymerase domain and requires just a small stretch of RNA-DNA.

Authors:  William P Bohlayer; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2006-06-20       Impact factor: 3.162

Review 7.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

8.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

9.  The effects of alternate polypurine tracts (PPTs) and mutations of sequences adjacent to the PPT on viral replication and cleavage specificity of the Rous sarcoma virus reverse transcriptase.

Authors:  Kevin W Chang; Jangsuk Oh; W Gregory Alvord; Stephen H Hughes
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Probing anomalous structural features in polypurine tract-containing RNA-DNA hybrids with neomycin B.

Authors:  Robert G Brinson; Kevin B Turner; Hye Young Yi-Brunozzi; Stuart F J Le Grice; Daniele Fabris; John P Marino
Journal:  Biochemistry       Date:  2009-07-28       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.